Table 1.

Clinical characteristics and MYC and BCL-2 expression.

Parameters		MYC (N=53)			BCL-2 (N=53)			DHS (N=53)
		>20%	≤20%	P value	>70%	≤70%	P value	0-1	2	P value
Gender	Male	17	15	0.652	15	17	0.911	22	10	0.505
	Female	9	12		11	10		17	4
Age	>=60	4	2	0.420	3	3	1.000	3	3	0.323
	<60	22	25		23	24		36	11
Ann Arbor stage	I-II	15	21	0.203	16	20	0.495	29	7	0.109
	III-IV	11	6		10	7		10	7
B symptoms	Yes	11	15	0.490	15	11	0.337	18	8	0.694
	No	15	12		11	16		21	6
LDH	Elevated	10	9	0.918	13	6	0.069	12	7	0.336
	Normal	16	18		13	21		27	7
ECOG PS	0-1	15	21	0.203	16	20	0.495	29	7	0.109
	>=2	11	6		10	7		10	7
Primary tumor site	Nasal cavity	16	20	0.495	13	23	0.014	30	6	0.042
	Extra-nasal	10	7		13	4		9	8
LTI	Yes	10	8	0.698	9	9	1.000	13	5	1.000
	No	16	19		17	18		26	9
Induction CT regimen	ASP-based	13	16	0.688	14	15	1.000	23	6	0.468
	Non-ASP-based	13	11		12	12		16	8
CT Response	CR	10	17	0.131	11	16	0.337	23	4	0.101
	Non-CR	16	10		15	11		16	10

Abbreviations: DHS, double hit score; LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; PS, performance status; LTI, local tumor invasion; CT, chemotherapy; ASP, asparaginase; CR, complete response.